The United Kingdom and the United States have agreed to a landmark bilateral deal that will preserve no import taxes on British medicine shipments being sold in the US market.
The Terms of the Accord
As part of the deal, the UK has committed to raise expenditure on medicines through the National Health Service (NHS). This move secures that import taxes on these crucial products will remain at zero for a timeframe of the next three years.
This agreement comes after earlier threats to hike duties on patented drug imports, with figures discussed as high as one hundred percent.
"This agreement with the Britain reinforces the international landscape for cutting-edge drugs and brings much-needed fairness to American-British drug exports," an announcement noted.
Trade Significance
Medicines represent one of the the United Kingdom's most significant export categories to the United States, which is clearly the primary destination for leading UK drugmakers.
Export figures show that in the 12 months prior to September, the UK sold pharmaceutical products totaling over eleven billion pounds to the US. This amount represented nearly one-fifth of all goods exports in that timeframe.
"This deal protects jobs, boosts investment and facilitates the UK to establish itself as a worldwide center for medical research," the Business and Trade Secretary commented.
Key NHS Changes
The deal involves several notable changes from the UK:
- Higher Cost Ceiling: The UK will lift the affordability limit at which it deems new therapies to be too expensive by twenty-five percent.
- Boosted Medicine Funding: There is a aim to raise overall public funding on treatments from 0.3 percent of the national economy to 0.6% over the following ten-year period.
- Rebate Cap: The amount pharmaceutical firms must refund to the NHS to prevent overspending will be restricted at 15%. Last year, repayments topped twenty percent.
Recent Tensions
The deal comes amid a ongoing dispute between the pharmaceutical industry and the British authorities over spending levels and NHS adoption.
The disagreement were intensified by assertions that American customers were charged a premium for the same drugs than patients in the UK and Europe.
In recent months, several major drug company projects in the UK have been delayed or cancelled, while multi-billion-dollar investments have been announced toward American operations.
A senior figure stated that the NHS needed to spend more on treatments, noting that its expenditure on drugs had declined as a percentage of its overall budget over the last ten years.
